GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 265,418 shares, a growth of 26.0% from the February 26th total of 210,698 shares. Currently, 14.6% of the company’s shares are sold short. Based on an average trading volume of 69,667 shares, the days-to-cover ratio is currently 3.8 days.

Analyst Ratings Changes

GOVX has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of GeoVax Labs to a “strong sell” rating in a research note on Saturday, January 17th. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a report on Thursday, February 19th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeoVax Labs currently has an average rating of “Hold” and an average price target of $187.50.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors have recently made changes to their positions in GOVX. Jane Street Group LLC bought a new stake in shares of GeoVax Labs in the first quarter valued at about $27,000. Sabby Management LLC bought a new position in GeoVax Labs during the 3rd quarter worth about $313,000. Armistice Capital LLC purchased a new position in GeoVax Labs during the 3rd quarter valued at about $253,000. Hudson Bay Capital Management LP bought a new stake in shares of GeoVax Labs in the 3rd quarter valued at about $47,000. Finally, Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter valued at about $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

GOVX traded down $0.05 during trading on Monday, hitting $1.35. 56,083 shares of the stock were exchanged, compared to its average volume of 140,845. The firm has a 50 day simple moving average of $2.06 and a 200 day simple moving average of $7.87. The firm has a market cap of $2.46 million, a price-to-earnings ratio of -0.04 and a beta of 3.81. GeoVax Labs has a 1 year low of $1.26 and a 1 year high of $34.75.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.